## Support your patient's next breath

AirLife® filtered nebulizer system




# Optimal medication delivery, minimal environmental effect

Our AirLife\* filtered nebulizer system was designed and tested for the clinical investigation of aerosolized pentamidine; however, it is suitable to deliver most any kind of aerosolized respiratory medication.

Its design and configuration help minimize the environmental impact of any aerosolized medication compared to a standard small volume nebulizer.

Air*Life*®





Cat. no:	Product description
124030EU	AirLife filtered nebulizer system, 20 per case

Performance specifications	
MMAD	3.5 +/- 0.2 <i>µ</i>
% respirable mass (1-5 μ):	54 +/- 0.4%
Respirable mass output rate (1-5 μ):	83 +/- 8 <i>μg</i> /min
Treatment time:	7.3 +/- 0.4 mins @ sputter + 1 min
Residual volume:	1.0 +/- 0.1 g

CareFusion Vernon Hills, IL

### carefusion.com

#### AirLife filtered nebulizer system\* performance reference list

NebuPent<sup>®</sup> (pentamidine isethionate) Package Insert. APP Pharmaceuticals Inc. (wholly-owned subsidiary of Fresenius-Kabi), 45847C. Revised: February 2008.

"After reconstitution with Sterile Water for Injection, USP, NebuPent is administered by inhalation via the Respirgard II nebulizer."

Actual pentamidine dose delivered by Respirgard II nebulizer. Kim C.S. et al; *Eur RespirJ* 1995. 8, 2178-2181.

"The findings from this initial study, although limited in that current aerosol characterization methodology was not used, are promising to support further study of the mean dose of pentamidine delivered to the lower airways in 20 minutes of treatment."

Comparison of nebuliser Efficiency for Aerosolizing Pentamidine. Smith D. et al. *Journal of Pharm & Pharmacology.* Vol 44, Issue 1, Jan 1992; 7-9.

"This study compares nebuliser efficiency in terms of drug output and droplet sizes of aerosolized pentamidine in four brands of jet nebuliser (Acorn-22, Inspiron, Cirrus, Respirgard II) and one brand of ultrasonic nebuliser (Fisoneb)."

Pulmonary deposition of aerosolized pentamidine using a new nebuliser: efficiency measurements *in vitro* and *in vivo*. Ferretti et al. *European Journal of Nuclear Medicine*. Vol 21. Issue 5. May 1994.399-406.

"We studied the performance of a new nebuliser (Pentasave) by comparison both in vitro and in vivo with a standard nebuliser (Respirgard II)."

#### Note

\* Formally known as RespirGard II nebulizer system.

